Uffe Søholm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Uffe Søholm has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Frans Pouwer
Department of Psychology University of Southern Denmark Odense Denmark
13 shared publications - Jane Speight
School of Psychology, Deakin University, Geelong, Victoria, Australia
13 shared publications - Stephanie A. Amiel
Department of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine King's College London London UK
12 shared publications - Pratik Choudhary
Diabetes Research Centre University of Leicester Leicester UK
11 shared publications - Natalie Zaremba
Department of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine King's College London London UK
10 shared publications - Bastiaan E. de Galan
Department of Internal Medicine Radboud University Medical Centre Nijmegen the Netherlands
9 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in Diabetic Medicine
- p. e70496
Capability, opportunity and motivation to support adults with type 1 diabetes experiencing fear of hypoglycaemia: A survey of Australian diabetes healthcare professionals
Aim: To explore the perceptions, experiences and unmet needs of diabetes healthcare professionals (DHPs) for supporting adults with type 1 diabetes (T1D) with fear of hypoglycaemia (FoH). Method: An online survey explored Australian DHPs' perceived capability, opportunity, motivation and behaviours related to supporting adults with T1D with FoH. DHPs were recruited via online advertisements, e‐newsletters and at conferences. Quantitative data were analysed using descriptive statistics, and qualitative data were analysed thematically. Results: A total of 106 eligible DHPs were included (83% credentialled diabetes educators, 92% women, mean (SD) age 49 (11) years), from all eight states/territories. DHPs indicated that FoH is experienced by almost two thirds of adults with T1D in their clinics. Most DHPs believe addressing FoH is within their scope of clinical practice (83%), and report motivation (89%) and capability (skills and confidence, 71% and 70% respectively) to do so. While more than half (50%–71%) perceive they have the social opportunity (e.g. social norms, workplace culture), few report physical opportunity (8%–24%), for example, access to validated screening tools; financial remuneration; affordable mental healthcare referral pathways. Free‐text responses highlighted the need for affordable and timely access to mental health professionals with knowledge about diabetes. Approximately eight out of ten would be (very) likely to refer those experiencing FoH to online self‐guided programs, if available. Conclusion: These findings show that Australian DHPs report the motivation and capability, but lack the opportunity to support adults with T1D experiencing FoH. Innovative referral pathways, including online self‐guided programmes, are perceived positively and may be useful in the Australian healthcare context.
- 14 October 2026
- Published by Wiley in Diabetic Medicine
- p. e70496
Open AccessCapability, opportunity and motivation to support adults with type 1 diabetes experiencing fear of hypoglycaemia: A survey of Australian diabetes healthcare professionals
Aim: To explore the perceptions, experiences and unmet needs of diabetes healthcare professionals (DHPs) for supporting adults with type 1 diabetes (T1D) with fear of hypoglycaemia (FoH). Method: An online survey explored Australian DHPs' perceived capability, opportunity, motivation and behaviours related to supporting adults with T1D with FoH. DHPs were recruited via online advertisements, e‐newsletters and at conferences. Quantitative data were analysed using descriptive statistics, and qualitative data were analysed thematically. Results: A total of 106 eligible DHPs were included (83% credentialled diabetes educators, 92% women, mean (SD) age 49 (11) years), from all eight states/territories. DHPs indicated that FoH is experienced by almost two thirds of adults with T1D in their clinics. Most DHPs believe addressing FoH is within their scope of clinical practice (83%), and report motivation (89%) and capability (skills and confidence, 71% and 70% respectively) to do so. While more than half (50%–71%) perceive they have the social opportunity (e.g. social norms, workplace culture), few report physical opportunity (8%–24%), for example, access to validated screening tools; financial remuneration; affordable mental healthcare referral pathways. Free‐text responses highlighted the need for affordable and timely access to mental health professionals with knowledge about diabetes. Approximately eight out of ten would be (very) likely to refer those experiencing FoH to online self‐guided programs, if available. Conclusion: These findings show that Australian DHPs report the motivation and capability, but lack the opportunity to support adults with T1D experiencing FoH. Innovative referral pathways, including online self‐guided programmes, are perceived positively and may be useful in the Australian healthcare context.
- Open Access
- 1 August 2026
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- p. 1-70
A lifelong approach to promote effective self-management in adults with type 1 diabetes: the DAFNEplus research programme including a cluster RCT
Background: Dose Adjustment For Normal Eating is a 5-day, group-based clinical education programme for adults with type 1 diabetes, training them in the complex self-management skills, enabling them to optimise both their glycaemic management and quality of life. Although Dose Adjustment For Normal Eating is associated with improvements in many aspects of diabetes management, including psychological outcomes, it has been challenging to maintain the biomedical improvements for longer term, which have remained well above the glucose levels recommended by National Institute for Health and Care Excellence. Objectives: We aimed to develop and evaluate Dose Adjustment For Normal Eating plus , an enhanced version of Dose Adjustment For Normal Eating, to enable improvements in glycaemic management (glycated haemoglobin) without compromising the quality of life. The objectives of the programme were to modify the existing Dose Adjustment For Normal Eating curriculum and evaluate it in a cluster randomised controlled trial. Design: This programme comprised four workstreams. The first three workstreams focused on redevelopment of the Dose Adjustment For Normal Eating intervention to become ‘Dose Adjustment For Normal Eating plus ’: involving revision of the curriculum for a 5-day, group-based programme, including relevant behaviour change techniques (workstream 1); development of a new structured, pro-active, follow-up programme to be delivered by Dose Adjustment For Normal Eating plus facilitators post course to support ongoing diabetes self-management (workstream 2); and development of a new technology interface to help glucose pattern recognition to inform improved self-management (workstream 3). We used mixed methods to review, develop and refine the Dose Adjustment For Normal Eating plus intervention (course, individual support and technological aspects). The intervention was piloted in three National Health Service specialist diabetes centres and was reviewed via two iterative waves before finalisation. Workstream 4 was a cluster randomised controlled trial using a pragmatic, parallel group (1 : 1) allocation design (Dose Adjustment For Normal Eating vs. Dose Adjustment For Normal Eating plus ), with concurrent process and health economic evaluations. The primary biomedical outcome was the between-group difference in glycated haemoglobin at 12 months. The primary psychological outcome was the between-group difference in the impact of type 1 diabetes on quality of life (using Audit of Diabetes-Dependent Quality of Life-15) at 12 months. Setting: The workstreams and the randomised controlled trial were undertaken in university and National Health Service specialist centres in England and Scotland. Participants: Four hundred and seventy-one adults aged ≥ 18 years with confirmed diagnosis of type 1 diabetes participated in the cluster randomised controlled trial, which was 144 fewer than planned and approximately 77% of the planned sample size. Intervention: Dose Adjustment For Normal Eating plus is a standardised 5-day educational course (described above), delivered 1 day per week over 5 weeks in groups, meeting face to face, followed by five individual support sessions over 12 months. An online platform supports the upload, visualisation, pattern recognition and review of glycaemic data for participants and clinicians. Trial outcome measures: In the cluster randomised controlled trial, the primary biomedical outcome was glycaemia, defined as glycated haemoglobin, at 12 months. The primary psychological outcome was the impact of diabetes on quality of life (assessed using the widely recognised scale, Audit of Diabetes-Dependent Quality of Life-15). Key secondary biomedical outcomes included rates and proportions of severe hypoglycaemia and diabetic ketoacidosis. Key secondary psychological outcomes included diabetes-specific distress, diabetes-specific positive well-being and fear of hypoglycaemia. Results: In the primary intention-to-treat population (309), mean glycated haemoglobin reduced from 9.1% to 8.2% (75.9–66.5 mmol/mol) in the Dose Adjustment For Normal Eating group and from 9.1% to 8.1% (75.6–65.1 mmol/mol) in the Dose Adjustment For Normal Eating plus group. The cluster randomised controlled trial showed no evidence of a between-group difference at 12 months in glycated haemoglobin {point estimate [95% confidence interval −0.014 (−0.284 to 0.255); p = 0.915]}, or diabetes-specific quality of life {point estimate [95% confidence interval 0.2 (−0.1 to 0.5); p = 0.21]}. At 12 months, significant between-group differences were observed, favouring Dose Adjustment For Normal Eating plus , in secondary psychological outcomes (diabetes-specific distress, diabetes-specific positive well-being and actions taken to avoid hypoglycaemia). Limitations: Due to trial-suspension during coronavirus disease, we recruited 471 adults to the cluster randomised controlled trial, 144 fewer than planned. Although this reduced overall statistical power, we showed that the difference in glycated haemoglobin between the groups was far below that we considered a meaningful clinical difference (0.5%). Recruitment also meant that more participants were using continuous glucose monitoring, both before and during the trial than we anticipated. This may have reduced additional benefit of the Dose Adjustment For Normal Eating plus intervention on glycated haemoglobin. The pandemic probably influenced diabetes self-management during the trial in both groups. Conclusions: Dose Adjustment For Normal Eating plus did not lead to greater falls in glycated haemoglobin at 12 months compared to Dose Adjustment For Normal Eating, but these falls were double those reported in previous Dose Adjustment For Normal Eating randomised controlled trials. Sixty-eight per cent of participants showed clinically relevant improved glucose levels. Those in Dose Adjustment For Normal Eating plus reported significant falls in diabetes distress, positive well-being and qualitative research reported positive experiences of Dose Adjustment For Normal Eating plus among participants and health professionals. Future work: In view of major improvements in diabetes distress and positive experiences in both participants and health professionals, the Dose Adjustment For Normal Eating executives, who co-ordinate the delivery of Dose Adjustment For Normal Eating courses, are planning to include key elements of Dose Adjustment For Normal Eating plus in future courses, particularly structured support to participants following the course and key elements of the curriculum. Study registration: This study is registered as IRAS: 235621 and ISRCTN: 42908016. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research Programme (NIHR award ref: RP-PG-0514-20013) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 21. See the NIHR Funding and Awards website for further award information.
- 1 August 2026
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- p. 1-70
Open AccessA lifelong approach to promote effective self-management in adults with type 1 diabetes: the DAFNEplus research programme including a cluster RCT
Background: Dose Adjustment For Normal Eating is a 5-day, group-based clinical education programme for adults with type 1 diabetes, training them in the complex self-management skills, enabling them to optimise both their glycaemic management and quality of life. Although Dose Adjustment For Normal Eating is associated with improvements in many aspects of diabetes management, including psychological outcomes, it has been challenging to maintain the biomedical improvements for longer term, which have remained well above the glucose levels recommended by National Institute for Health and Care Excellence. Objectives: We aimed to develop and evaluate Dose Adjustment For Normal Eating plus , an enhanced version of Dose Adjustment For Normal Eating, to enable improvements in glycaemic management (glycated haemoglobin) without compromising the quality of life. The objectives of the programme were to modify the existing Dose Adjustment For Normal Eating curriculum and evaluate it in a cluster randomised controlled trial. Design: This programme comprised four workstreams. The first three workstreams focused on redevelopment of the Dose Adjustment For Normal Eating intervention to become ‘Dose Adjustment For Normal Eating plus ’: involving revision of the curriculum for a 5-day, group-based programme, including relevant behaviour change techniques (workstream 1); development of a new structured, pro-active, follow-up programme to be delivered by Dose Adjustment For Normal Eating plus facilitators post course to support ongoing diabetes self-management (workstream 2); and development of a new technology interface to help glucose pattern recognition to inform improved self-management (workstream 3). We used mixed methods to review, develop and refine the Dose Adjustment For Normal Eating plus intervention (course, individual support and technological aspects). The intervention was piloted in three National Health Service specialist diabetes centres and was reviewed via two iterative waves before finalisation. Workstream 4 was a cluster randomised controlled trial using a pragmatic, parallel group (1 : 1) allocation design (Dose Adjustment For Normal Eating vs. Dose Adjustment For Normal Eating plus ), with concurrent process and health economic evaluations. The primary biomedical outcome was the between-group difference in glycated haemoglobin at 12 months. The primary psychological outcome was the between-group difference in the impact of type 1 diabetes on quality of life (using Audit of Diabetes-Dependent Quality of Life-15) at 12 months. Setting: The workstreams and the randomised controlled trial were undertaken in university and National Health Service specialist centres in England and Scotland. Participants: Four hundred and seventy-one adults aged ≥ 18 years with confirmed diagnosis of type 1 diabetes participated in the cluster randomised controlled trial, which was 144 fewer than planned and approximately 77% of the planned sample size. Intervention: Dose Adjustment For Normal Eating plus is a standardised 5-day educational course (described above), delivered 1 day per week over 5 weeks in groups, meeting face to face, followed by five individual support sessions over 12 months. An online platform supports the upload, visualisation, pattern recognition and review of glycaemic data for participants and clinicians. Trial outcome measures: In the cluster randomised controlled trial, the primary biomedical outcome was glycaemia, defined as glycated haemoglobin, at 12 months. The primary psychological outcome was the impact of diabetes on quality of life (assessed using the widely recognised scale, Audit of Diabetes-Dependent Quality of Life-15). Key secondary biomedical outcomes included rates and proportions of severe hypoglycaemia and diabetic ketoacidosis. Key secondary psychological outcomes included diabetes-specific distress, diabetes-specific positive well-being and fear of hypoglycaemia. Results: In the primary intention-to-treat population (309), mean glycated haemoglobin reduced from 9.1% to 8.2% (75.9–66.5 mmol/mol) in the Dose Adjustment For Normal Eating group and from 9.1% to 8.1% (75.6–65.1 mmol/mol) in the Dose Adjustment For Normal Eating plus group. The cluster randomised controlled trial showed no evidence of a between-group difference at 12 months in glycated haemoglobin {point estimate [95% confidence interval −0.014 (−0.284 to 0.255); p = 0.915]}, or diabetes-specific quality of life {point estimate [95% confidence interval 0.2 (−0.1 to 0.5); p = 0.21]}. At 12 months, significant between-group differences were observed, favouring Dose Adjustment For Normal Eating plus , in secondary psychological outcomes (diabetes-specific distress, diabetes-specific positive well-being and actions taken to avoid hypoglycaemia). Limitations: Due to trial-suspension during coronavirus disease, we recruited 471 adults to the cluster randomised controlled trial, 144 fewer than planned. Although this reduced overall statistical power, we showed that the difference in glycated haemoglobin between the groups was far below that we considered a meaningful clinical difference (0.5%). Recruitment also meant that more participants were using continuous glucose monitoring, both before and during the trial than we anticipated. This may have reduced additional benefit of the Dose Adjustment For Normal Eating plus intervention on glycated haemoglobin. The pandemic probably influenced diabetes self-management during the trial in both groups. Conclusions: Dose Adjustment For Normal Eating plus did not lead to greater falls in glycated haemoglobin at 12 months compared to Dose Adjustment For Normal Eating, but these falls were double those reported in previous Dose Adjustment For Normal Eating randomised controlled trials. Sixty-eight per cent of participants showed clinically relevant improved glucose levels. Those in Dose Adjustment For Normal Eating plus reported significant falls in diabetes distress, positive well-being and qualitative research reported positive experiences of Dose Adjustment For Normal Eating plus among participants and health professionals. Future work: In view of major improvements in diabetes distress and positive experiences in both participants and health professionals, the Dose Adjustment For Normal Eating executives, who co-ordinate the delivery of Dose Adjustment For Normal Eating courses, are planning to include key elements of Dose Adjustment For Normal Eating plus in future courses, particularly structured support to participants following the course and key elements of the curriculum. Study registration: This study is registered as IRAS: 235621 and ISRCTN: 42908016. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research Programme (NIHR award ref: RP-PG-0514-20013) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 21. See the NIHR Funding and Awards website for further award information.
- Open Access
- 30 June 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 9685-9690
Hypoglycaemia Was Not Associated With Depression, Anxiety, Diabetes Distress or Fear of Hypoglycaemia Scores in People With Type 1 or Insulin‐Treated Type 2 Diabetes in the Hypo‐ METRICS Study
- 30 June 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 9685-9690
Open AccessHypoglycaemia Was Not Associated With Depression, Anxiety, Diabetes Distress or Fear of Hypoglycaemia Scores in People With Type 1 or Insulin‐Treated Type 2 Diabetes in the Hypo‐ METRICS Study
- Open Access
- 29 March 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (8) , e70301
Exploring the gap between sensor‐detected ( SDH ) and person‐reported hypoglycaemia ( PRH ): The voice of people living with diabetes
Background and Aims: In people with insulin‐treated diabetes experiencing hypoglycaemia, the multicentre Hypo‐METRICS study found that 60% of sensor‐detected hypoglycaemic episodes (SDH) were asymptomatic, and over 40% of person‐reported hypoglycaemia (PRH) occurred at glucose levels ≥70 mg/dL (3.9 mmol/L). This subanalysis explored participants' experiences of these episodes to identify possible clinical implications. Methods: Fifty‐eight Austrian participants received a 15‐item questionnaire on their experience of asymptomatic hypoglycaemia and symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L). Results: The response rate was 86% ( n = 50). Among all participants, 56% ( n = 28) reported experiencing hypoglycaemic symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L) “sometimes” or “often.” They attributed this to a combination of a threshold shift due to chronic hyperglycaemia, rapid glucose decline and fear of hypoglycaemia. 68% of all SDH < 70 mg/dL and 59% of those below the clinically critical level of 54 mg/dL were asymptomatic. Conclusion: These results demonstrate that SDH and PRH each capture different, yet equally important, dimensions of the hypoglycaemia experience. Relying on only one source of information inevitably provides an incomplete picture. By integrating the patient's voice, diabetes professionals can provide appropriate support and tailor continuous glucose monitoring (CGM) alarm settings and treatment plans to truly meet individual needs.
- 29 March 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (8) , e70301
Open AccessExploring the gap between sensor‐detected ( SDH ) and person‐reported hypoglycaemia ( PRH ): The voice of people living with diabetes
Background and Aims: In people with insulin‐treated diabetes experiencing hypoglycaemia, the multicentre Hypo‐METRICS study found that 60% of sensor‐detected hypoglycaemic episodes (SDH) were asymptomatic, and over 40% of person‐reported hypoglycaemia (PRH) occurred at glucose levels ≥70 mg/dL (3.9 mmol/L). This subanalysis explored participants' experiences of these episodes to identify possible clinical implications. Methods: Fifty‐eight Austrian participants received a 15‐item questionnaire on their experience of asymptomatic hypoglycaemia and symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L). Results: The response rate was 86% ( n = 50). Among all participants, 56% ( n = 28) reported experiencing hypoglycaemic symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L) “sometimes” or “often.” They attributed this to a combination of a threshold shift due to chronic hyperglycaemia, rapid glucose decline and fear of hypoglycaemia. 68% of all SDH < 70 mg/dL and 59% of those below the clinically critical level of 54 mg/dL were asymptomatic. Conclusion: These results demonstrate that SDH and PRH each capture different, yet equally important, dimensions of the hypoglycaemia experience. Relying on only one source of information inevitably provides an incomplete picture. By integrating the patient's voice, diabetes professionals can provide appropriate support and tailor continuous glucose monitoring (CGM) alarm settings and treatment plans to truly meet individual needs.
- Open Access
- 3 February 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (4) , e70231
Assessing thoughts, feelings and behaviours related to hypoglycaemia: Psychometric evaluation of the Hypoglycaemia Cues Questionnaire ( HypoC ‐Q)
Aims: To describe the design and examine the psychometric properties of the Hypoglycaemia Cues Questionnaire (HypoC‐Q) for assessing thoughts, feelings, and behaviours related to hypoglycaemia among adults with type 1 diabetes (T1D). Methods: The HypoC‐Q was designed iteratively, informed by exploratory interviews with 17 adults with T1D with impaired awareness of hypoglycaemia and/or recurrent severe hypoglycaemia, and consultation with diabetologists. Psychometric analyses were completed on baseline data from the Hypo‐METRICS study. Data from adults with T1D, reporting at least one hypoglycaemic event, were eligible if they had completed the baseline HypoC‐Q. Completion rates, latent structure, internal consistency, construct and known‐groups validity were examined. Results: In Hypo‐METRICS, 154 participants (62% females; mean ± SD age 44 ± 15 years; T1D duration: 23 ± 16 years) were eligible. All completed all 40 HypoC‐Q items, demonstrating its acceptability. Exploratory factor analysis identified four scales with satisfactory internal consistency ( α = 0.69–0.81): 1) low concern (7 items), 2) burnout (6 items), 3) missing cues (5 items), and 4) delaying treatment (9 items); plus eight items, treated separately. Construct validity was supported by significant moderate correlations between ‘burnout’ and fear of hypoglycaemia and diabetes distress, and between ‘missing’ and ‘delay’ with impaired awareness of hypoglycaemia; all three distinguished between those with intact and impaired awareness (known‐groups validity); but not by history of severe hypoglycaemia. Conclusions: The HypoC‐Q is an acceptable, valid, and reliable measure of thoughts, feelings, and behaviours related to hypoglycaemia among adults with T1D. It is available for informing and assessing the effect of interventions to reduce hypoglycaemia exposure and impact.
- 3 February 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (4) , e70231
Open AccessAssessing thoughts, feelings and behaviours related to hypoglycaemia: Psychometric evaluation of the Hypoglycaemia Cues Questionnaire ( HypoC ‐Q)
Aims: To describe the design and examine the psychometric properties of the Hypoglycaemia Cues Questionnaire (HypoC‐Q) for assessing thoughts, feelings, and behaviours related to hypoglycaemia among adults with type 1 diabetes (T1D). Methods: The HypoC‐Q was designed iteratively, informed by exploratory interviews with 17 adults with T1D with impaired awareness of hypoglycaemia and/or recurrent severe hypoglycaemia, and consultation with diabetologists. Psychometric analyses were completed on baseline data from the Hypo‐METRICS study. Data from adults with T1D, reporting at least one hypoglycaemic event, were eligible if they had completed the baseline HypoC‐Q. Completion rates, latent structure, internal consistency, construct and known‐groups validity were examined. Results: In Hypo‐METRICS, 154 participants (62% females; mean ± SD age 44 ± 15 years; T1D duration: 23 ± 16 years) were eligible. All completed all 40 HypoC‐Q items, demonstrating its acceptability. Exploratory factor analysis identified four scales with satisfactory internal consistency ( α = 0.69–0.81): 1) low concern (7 items), 2) burnout (6 items), 3) missing cues (5 items), and 4) delaying treatment (9 items); plus eight items, treated separately. Construct validity was supported by significant moderate correlations between ‘burnout’ and fear of hypoglycaemia and diabetes distress, and between ‘missing’ and ‘delay’ with impaired awareness of hypoglycaemia; all three distinguished between those with intact and impaired awareness (known‐groups validity); but not by history of severe hypoglycaemia. Conclusions: The HypoC‐Q is an acceptable, valid, and reliable measure of thoughts, feelings, and behaviours related to hypoglycaemia among adults with T1D. It is available for informing and assessing the effect of interventions to reduce hypoglycaemia exposure and impact.
- Open Access
- 30 December 2025
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70185
User evaluation of the Hypo‐METRICS app: A tool for real‐time symptom reporting of hypoglycaemia
Aims: Hypoglycaemia remains a barrier to optimal diabetes management, with few tools for capturing real‐time person‐reported hypoglycaemia (PRH). This study evaluated the Hypo‐METRICS app, originally developed for a multinational 10‐week prospective study of hypoglycaemia. It enables real‐time reporting of hypoglycaemic episodes and their impact on daily functioning using Ecological Momentary Assessment (EMA), thereby overcoming limitations of retrospective self reports. Methods: After completing the Hypo‐METRICS study, 120 participants with type 1 diabetes mellitus (T1D) or type 2 diabetes mellitus (T2D) from Austria, Denmark, the Netherlands, and the United Kingdom were invited to complete a web‐based questionnaire assessing app content, functionality, intervention effects, user engagement and the influence of the Covid‐19 pandemic. Results: Ninety‐six participants (80%; 29 T1D, 67 T2D) completed the questionnaire (40% women; mean age 57.2 ± 16.1 years; 26% impaired hypoglycaemia awareness; HbA1c 60 ± 13 mmol/mol (7.6 ± 1.1%); diabetes duration 20.4 ± 11.3 years). App content and functionality were rated highly (>8/10 and >7/10, respectively). Some reported declining engagement, likely due to study length. COVID‐19 had a minimal impact on app use. Conclusions: The Hypo‐METRICS app was well accepted, with strong ratings for usability and functionality. Given its unique strengths, the app has the potential to become an essential instrument for researchers aiming to capture the real‐world burden and impact of hypoglycaemia.
- 30 December 2025
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70185
Open AccessUser evaluation of the Hypo‐METRICS app: A tool for real‐time symptom reporting of hypoglycaemia
Aims: Hypoglycaemia remains a barrier to optimal diabetes management, with few tools for capturing real‐time person‐reported hypoglycaemia (PRH). This study evaluated the Hypo‐METRICS app, originally developed for a multinational 10‐week prospective study of hypoglycaemia. It enables real‐time reporting of hypoglycaemic episodes and their impact on daily functioning using Ecological Momentary Assessment (EMA), thereby overcoming limitations of retrospective self reports. Methods: After completing the Hypo‐METRICS study, 120 participants with type 1 diabetes mellitus (T1D) or type 2 diabetes mellitus (T2D) from Austria, Denmark, the Netherlands, and the United Kingdom were invited to complete a web‐based questionnaire assessing app content, functionality, intervention effects, user engagement and the influence of the Covid‐19 pandemic. Results: Ninety‐six participants (80%; 29 T1D, 67 T2D) completed the questionnaire (40% women; mean age 57.2 ± 16.1 years; 26% impaired hypoglycaemia awareness; HbA1c 60 ± 13 mmol/mol (7.6 ± 1.1%); diabetes duration 20.4 ± 11.3 years). App content and functionality were rated highly (>8/10 and >7/10, respectively). Some reported declining engagement, likely due to study length. COVID‐19 had a minimal impact on app use. Conclusions: The Hypo‐METRICS app was well accepted, with strong ratings for usability and functionality. Given its unique strengths, the app has the potential to become an essential instrument for researchers aiming to capture the real‐world burden and impact of hypoglycaemia.
- Open Access
- 2 July 2025
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 46, 101513
Statistical analysis plan for the 24-week randomised trial of hypoglycaemia prevention, awareness of symptoms, and treatment: HypoPAST
- 2 July 2025
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 46, 101513
Open AccessStatistical analysis plan for the 24-week randomised trial of hypoglycaemia prevention, awareness of symptoms, and treatment: HypoPAST
- Open Access
- 11 January 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (5) , e15514
The missing piece: The clinical translation of precision diabetes medicine requires precision mental health care: A call to action from the international PsychoSocial Aspects of Diabetes (PSAD) Study Group
- 11 January 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (5) , e15514
Open AccessThe missing piece: The clinical translation of precision diabetes medicine requires precision mental health care: A call to action from the international PsychoSocial Aspects of Diabetes (PSAD) Study Group
- Open Access
- 29 October 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-19
Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST): protocol for a 24-week hybrid type 1 randomised controlled trial of a fully online psycho-educational programme for adults with type 1 diabetes
Background: Management of type 1 diabetes (T1D) requires the use of insulin, which can cause hypoglycaemia (low blood glucose levels). While most hypoglycaemic episodes can be self-treated, all episodes can be sudden, inconvenient, challenging to prevent or manage, unpleasant and/or cause unwanted attention or embarrassment. Severe hypoglycaemic episodes, requiring assistance from others for recovery, are rare but potentially dangerous. Repeated exposure to hypoglycaemia can reduce classic warning symptoms (‘awareness’), thereby increasing risk of severe episodes. Thus, fear of hypoglycaemia is common among adults with T1D and can have a negative impact on how they manage their diabetes, as well as on daily functioning, well-being and quality of life. While advances in glycaemic technologies and group-based psycho-educational programmes can reduce fear, frequency and impact of hypoglycaemia, they are not universally or freely available, nor do they fully resolve problematic hypoglycaemia or associated worries. This study aims to determine the effectiveness of a fully online, self-directed, scalable, psycho-educational intervention for reducing fear of hypoglycaemia: the Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST) programme. Methods: A 24-week, two-arm, parallel-group, hybrid type 1 randomised controlled trial, conducted remotely (online and telephone). Australian adults (≥ 18 years) with self-reported T1D and fear of hypoglycaemia will be recruited, and allocated at random (1:1) to HypoPAST or control (usual care). The primary outcome is the between-group difference in fear of hypoglycaemia (assessed using HFS-II Worry score) at 24 weeks. A sample size of N = 196 is required to detect a 9-point difference, with 90% power and allowing for 30% attrition. Multiple secondary outcomes include self-reported psychological, behavioural, biomedical, health economic, and process evaluation data. Data will be collected at baseline, 12 and 24 weeks using online surveys, 2-week ecological momentary assessments, website analytics and semi-structured interviews. Discussion: This study will provide evidence regarding the effectiveness, cost-effectiveness and acceptability of a novel, online psycho-educational programme: HypoPAST. Due to the fully online format, HypoPAST is expected to provide an inexpensive, convenient, accessible and scalable solution for reducing fear of hypoglycaemia among adults with T1D. Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12623000894695 (21 August 2023).
- 29 October 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-19
Open AccessHypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST): protocol for a 24-week hybrid type 1 randomised controlled trial of a fully online psycho-educational programme for adults with type 1 diabetes
Background: Management of type 1 diabetes (T1D) requires the use of insulin, which can cause hypoglycaemia (low blood glucose levels). While most hypoglycaemic episodes can be self-treated, all episodes can be sudden, inconvenient, challenging to prevent or manage, unpleasant and/or cause unwanted attention or embarrassment. Severe hypoglycaemic episodes, requiring assistance from others for recovery, are rare but potentially dangerous. Repeated exposure to hypoglycaemia can reduce classic warning symptoms (‘awareness’), thereby increasing risk of severe episodes. Thus, fear of hypoglycaemia is common among adults with T1D and can have a negative impact on how they manage their diabetes, as well as on daily functioning, well-being and quality of life. While advances in glycaemic technologies and group-based psycho-educational programmes can reduce fear, frequency and impact of hypoglycaemia, they are not universally or freely available, nor do they fully resolve problematic hypoglycaemia or associated worries. This study aims to determine the effectiveness of a fully online, self-directed, scalable, psycho-educational intervention for reducing fear of hypoglycaemia: the Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST) programme. Methods: A 24-week, two-arm, parallel-group, hybrid type 1 randomised controlled trial, conducted remotely (online and telephone). Australian adults (≥ 18 years) with self-reported T1D and fear of hypoglycaemia will be recruited, and allocated at random (1:1) to HypoPAST or control (usual care). The primary outcome is the between-group difference in fear of hypoglycaemia (assessed using HFS-II Worry score) at 24 weeks. A sample size of N = 196 is required to detect a 9-point difference, with 90% power and allowing for 30% attrition. Multiple secondary outcomes include self-reported psychological, behavioural, biomedical, health economic, and process evaluation data. Data will be collected at baseline, 12 and 24 weeks using online surveys, 2-week ecological momentary assessments, website analytics and semi-structured interviews. Discussion: This study will provide evidence regarding the effectiveness, cost-effectiveness and acceptability of a novel, online psycho-educational programme: HypoPAST. Due to the fully online format, HypoPAST is expected to provide an inexpensive, convenient, accessible and scalable solution for reducing fear of hypoglycaemia among adults with T1D. Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12623000894695 (21 August 2023).
- Open Access
- 30 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (10) , 2160-2174
The impact of hypoglycaemia on daily functioning among adults with diabetes: a prospective observational study using the Hypo-METRICS app
Aims/hypothesis: The aim of this work was to examine the impact of hypoglycaemia on daily functioning among adults with type 1 diabetes or insulin-treated type 2 diabetes, using the novel Hypo-METRICS app. Methods: For 70 consecutive days, 594 adults (type 1 diabetes, n=274; type 2 diabetes, n=320) completed brief morning and evening Hypo-METRICS ‘check-ins’ about their experienced hypoglycaemia and daily functioning. Participants wore a blinded glucose sensor (i.e. data unavailable to the participants) for the study duration. Days and nights with or without person-reported hypoglycaemia (PRH) and/or sensor-detected hypoglycaemia (SDH) were compared using multilevel regression models. Results: Participants submitted a mean ± SD of 86.3±12.5% morning and 90.8±10.7% evening check-ins. For both types of diabetes, SDH alone had no significant associations with the changes in daily functioning scores. However, daytime and night-time PRH (with or without SDH) were significantly associated with worsening of energy levels, mood, cognitive functioning, negative affect and fear of hypoglycaemia later that day or while asleep. In addition, night-time PRH (with or without SDH) was significantly associated with worsening of sleep quality (type 1 and type 2 diabetes) and memory (type 2 diabetes). Further, daytime PRH (with or without SDH), was associated with worsening of fear of hyperglycaemia while asleep (type 1 diabetes), memory (type 1 and type 2 diabetes) and social functioning (type 2 diabetes). Conclusions/interpretation: This prospective, real-world study reveals impact on several domains of daily functioning following PRH but not following SDH alone. These data suggest that the observed negative impact is mainly driven by subjective awareness of hypoglycaemia (i.e. PRH), through either symptoms or sensor alerts/readings and/or the need to take action to prevent or treat episodes. Graphical
- 30 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (10) , 2160-2174
Open AccessThe impact of hypoglycaemia on daily functioning among adults with diabetes: a prospective observational study using the Hypo-METRICS app
Aims/hypothesis: The aim of this work was to examine the impact of hypoglycaemia on daily functioning among adults with type 1 diabetes or insulin-treated type 2 diabetes, using the novel Hypo-METRICS app. Methods: For 70 consecutive days, 594 adults (type 1 diabetes, n=274; type 2 diabetes, n=320) completed brief morning and evening Hypo-METRICS ‘check-ins’ about their experienced hypoglycaemia and daily functioning. Participants wore a blinded glucose sensor (i.e. data unavailable to the participants) for the study duration. Days and nights with or without person-reported hypoglycaemia (PRH) and/or sensor-detected hypoglycaemia (SDH) were compared using multilevel regression models. Results: Participants submitted a mean ± SD of 86.3±12.5% morning and 90.8±10.7% evening check-ins. For both types of diabetes, SDH alone had no significant associations with the changes in daily functioning scores. However, daytime and night-time PRH (with or without SDH) were significantly associated with worsening of energy levels, mood, cognitive functioning, negative affect and fear of hypoglycaemia later that day or while asleep. In addition, night-time PRH (with or without SDH) was significantly associated with worsening of sleep quality (type 1 and type 2 diabetes) and memory (type 2 diabetes). Further, daytime PRH (with or without SDH), was associated with worsening of fear of hyperglycaemia while asleep (type 1 diabetes), memory (type 1 and type 2 diabetes) and social functioning (type 2 diabetes). Conclusions/interpretation: This prospective, real-world study reveals impact on several domains of daily functioning following PRH but not following SDH alone. These data suggest that the observed negative impact is mainly driven by subjective awareness of hypoglycaemia (i.e. PRH), through either symptoms or sensor alerts/readings and/or the need to take action to prevent or treat episodes. Graphical